Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy

H. Richard Alexander, Steven K. Libutti, David L. Bartlett, James F. Pingpank, Karen Kranda, Cynthia Helsabeck, Tatiana Beresnev

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

BACKGROUND. Many patients with colorectal carcinoma develop unresectable metastases confined to the liver that remain the life-limiting component of disease despite best available systemic or regional chemotherapy. In the current study, the authors present their results using vascular isolation and perfusion of the liver for individuals with progressive, unresectable liver metastases from colorectal carcinoma that were refractory to both previous systemic and regional chemotherapy. METHODS. Seven patients with refractory, progressive, unresectable colorectal carcinoma metastases confined to the liver underwent a 60-minute hyperthermic (39-40 °C) isolated hepatic perfusion (IHP) and were followed for toxicity, response, and survival. RESULTS. There was no surgical- or treatment-related mortality; all patients experienced transient Grade 3-4 (according to National Cancer Institute common toxicity criteria) hepatic toxicity. At a median potential follow-up of 16 months, the overall objective radiographic response rate (all partial responses) was 71% (5 of 7 assessable patients). It is interesting to note that two patients who were treated with tumor necrosis factor (TNF) alone demonstrated no response to therapy compared with all five patients who were treated with melphalan and TNF (three patients) or melphalan alone (two patients). For the 5 patients who responded to treatment, the median duration of response was 10 months (range, 10-13 months) and in all 7 patients the mean overall survival was 19.7 months (range, 2-33 months), including 5 months and 7.5 months, respectively, for the 2 patients treated with TNF alone. CONCLUSIONS. The results of the current study demonstrate that IHP using melphalan with or without TNF has significant antitumor activity in this patient population. IHP deserves continued clinical evaluation as a therapeutic modality for patients with unresectable colorectal carcinoma metastases to the liver.

Original languageEnglish (US)
Pages (from-to)730-736
Number of pages7
JournalCancer
Volume95
Issue number4
DOIs
StatePublished - Aug 15 2002
Externally publishedYes

Fingerprint

Patient Isolation
Blood Vessels
Colorectal Neoplasms
Perfusion
Neoplasm Metastasis
Drug Therapy
Liver
Melphalan
Tumor Necrosis Factor-alpha
Survival
National Cancer Institute (U.S.)
Therapeutics

Keywords

  • Colorectal carcinoma
  • Hyperthermia
  • Isolation perfusion
  • Liver metastases
  • Regional chemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy. / Alexander, H. Richard; Libutti, Steven K.; Bartlett, David L.; Pingpank, James F.; Kranda, Karen; Helsabeck, Cynthia; Beresnev, Tatiana.

In: Cancer, Vol. 95, No. 4, 15.08.2002, p. 730-736.

Research output: Contribution to journalArticle

Alexander, H. Richard ; Libutti, Steven K. ; Bartlett, David L. ; Pingpank, James F. ; Kranda, Karen ; Helsabeck, Cynthia ; Beresnev, Tatiana. / Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy. In: Cancer. 2002 ; Vol. 95, No. 4. pp. 730-736.
@article{7abea2a92f25472883e45f6d8f6a702a,
title = "Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy",
abstract = "BACKGROUND. Many patients with colorectal carcinoma develop unresectable metastases confined to the liver that remain the life-limiting component of disease despite best available systemic or regional chemotherapy. In the current study, the authors present their results using vascular isolation and perfusion of the liver for individuals with progressive, unresectable liver metastases from colorectal carcinoma that were refractory to both previous systemic and regional chemotherapy. METHODS. Seven patients with refractory, progressive, unresectable colorectal carcinoma metastases confined to the liver underwent a 60-minute hyperthermic (39-40 °C) isolated hepatic perfusion (IHP) and were followed for toxicity, response, and survival. RESULTS. There was no surgical- or treatment-related mortality; all patients experienced transient Grade 3-4 (according to National Cancer Institute common toxicity criteria) hepatic toxicity. At a median potential follow-up of 16 months, the overall objective radiographic response rate (all partial responses) was 71{\%} (5 of 7 assessable patients). It is interesting to note that two patients who were treated with tumor necrosis factor (TNF) alone demonstrated no response to therapy compared with all five patients who were treated with melphalan and TNF (three patients) or melphalan alone (two patients). For the 5 patients who responded to treatment, the median duration of response was 10 months (range, 10-13 months) and in all 7 patients the mean overall survival was 19.7 months (range, 2-33 months), including 5 months and 7.5 months, respectively, for the 2 patients treated with TNF alone. CONCLUSIONS. The results of the current study demonstrate that IHP using melphalan with or without TNF has significant antitumor activity in this patient population. IHP deserves continued clinical evaluation as a therapeutic modality for patients with unresectable colorectal carcinoma metastases to the liver.",
keywords = "Colorectal carcinoma, Hyperthermia, Isolation perfusion, Liver metastases, Regional chemotherapy",
author = "Alexander, {H. Richard} and Libutti, {Steven K.} and Bartlett, {David L.} and Pingpank, {James F.} and Karen Kranda and Cynthia Helsabeck and Tatiana Beresnev",
year = "2002",
month = "8",
day = "15",
doi = "10.1002/cncr.10686",
language = "English (US)",
volume = "95",
pages = "730--736",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy

AU - Alexander, H. Richard

AU - Libutti, Steven K.

AU - Bartlett, David L.

AU - Pingpank, James F.

AU - Kranda, Karen

AU - Helsabeck, Cynthia

AU - Beresnev, Tatiana

PY - 2002/8/15

Y1 - 2002/8/15

N2 - BACKGROUND. Many patients with colorectal carcinoma develop unresectable metastases confined to the liver that remain the life-limiting component of disease despite best available systemic or regional chemotherapy. In the current study, the authors present their results using vascular isolation and perfusion of the liver for individuals with progressive, unresectable liver metastases from colorectal carcinoma that were refractory to both previous systemic and regional chemotherapy. METHODS. Seven patients with refractory, progressive, unresectable colorectal carcinoma metastases confined to the liver underwent a 60-minute hyperthermic (39-40 °C) isolated hepatic perfusion (IHP) and were followed for toxicity, response, and survival. RESULTS. There was no surgical- or treatment-related mortality; all patients experienced transient Grade 3-4 (according to National Cancer Institute common toxicity criteria) hepatic toxicity. At a median potential follow-up of 16 months, the overall objective radiographic response rate (all partial responses) was 71% (5 of 7 assessable patients). It is interesting to note that two patients who were treated with tumor necrosis factor (TNF) alone demonstrated no response to therapy compared with all five patients who were treated with melphalan and TNF (three patients) or melphalan alone (two patients). For the 5 patients who responded to treatment, the median duration of response was 10 months (range, 10-13 months) and in all 7 patients the mean overall survival was 19.7 months (range, 2-33 months), including 5 months and 7.5 months, respectively, for the 2 patients treated with TNF alone. CONCLUSIONS. The results of the current study demonstrate that IHP using melphalan with or without TNF has significant antitumor activity in this patient population. IHP deserves continued clinical evaluation as a therapeutic modality for patients with unresectable colorectal carcinoma metastases to the liver.

AB - BACKGROUND. Many patients with colorectal carcinoma develop unresectable metastases confined to the liver that remain the life-limiting component of disease despite best available systemic or regional chemotherapy. In the current study, the authors present their results using vascular isolation and perfusion of the liver for individuals with progressive, unresectable liver metastases from colorectal carcinoma that were refractory to both previous systemic and regional chemotherapy. METHODS. Seven patients with refractory, progressive, unresectable colorectal carcinoma metastases confined to the liver underwent a 60-minute hyperthermic (39-40 °C) isolated hepatic perfusion (IHP) and were followed for toxicity, response, and survival. RESULTS. There was no surgical- or treatment-related mortality; all patients experienced transient Grade 3-4 (according to National Cancer Institute common toxicity criteria) hepatic toxicity. At a median potential follow-up of 16 months, the overall objective radiographic response rate (all partial responses) was 71% (5 of 7 assessable patients). It is interesting to note that two patients who were treated with tumor necrosis factor (TNF) alone demonstrated no response to therapy compared with all five patients who were treated with melphalan and TNF (three patients) or melphalan alone (two patients). For the 5 patients who responded to treatment, the median duration of response was 10 months (range, 10-13 months) and in all 7 patients the mean overall survival was 19.7 months (range, 2-33 months), including 5 months and 7.5 months, respectively, for the 2 patients treated with TNF alone. CONCLUSIONS. The results of the current study demonstrate that IHP using melphalan with or without TNF has significant antitumor activity in this patient population. IHP deserves continued clinical evaluation as a therapeutic modality for patients with unresectable colorectal carcinoma metastases to the liver.

KW - Colorectal carcinoma

KW - Hyperthermia

KW - Isolation perfusion

KW - Liver metastases

KW - Regional chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0037103087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037103087&partnerID=8YFLogxK

U2 - 10.1002/cncr.10686

DO - 10.1002/cncr.10686

M3 - Article

C2 - 12209715

AN - SCOPUS:0037103087

VL - 95

SP - 730

EP - 736

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -